SCHEMBL1749377

SCHEMBL1749377

COCCNCc1ccnc2[nH]c(-c3cn(C)c4cc(OC)c(OC)cc34)cc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 3/20 0.57
LCK P06239 2/20 0.44
GSK3A P49840 2/20 0.44
GSK3B P49841 2/20 0.44
CDK7 P50613 2/20 0.44
LRRK2 Q5S007 2/20 0.44
AURKB Q96GD4 2/20 0.44
JAK2 O60674 1/20 0.44
BTK Q06187 1/20 0.44
CDK9 P50750 12/20 0.37
MAPK8 P45983 2/20 0.37
AURKA O14965 1/20 0.37
PAK4 O96013 1/20 0.37
ABL1 P00519 1/20 0.37
NTRK1 P04629 1/20 0.37
FYN P06241 1/20 0.37
CSF1R P07333 1/20 0.37
RET P07949 1/20 0.37
MET P08581 1/20 0.37
PDGFRB P09619 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1749159 0.87 IGF1R (0.56) IGF1RLCKGSK3AGSK3BCDK7
SCHEMBL1748950 0.86 IGF1R (0.59) IGF1RLCKGSK3AGSK3BCDK7
SCHEMBL1749253 0.86 IGF1R (0.55) IGF1RLCKGSK3AGSK3BCDK7
SCHEMBL1748735 0.85 IGF1R (0.56) IGF1RLCKGSK3AGSK3BCDK7
SCHEMBL1748832 0.84 IGF1R (0.55) IGF1RLCKGSK3AGSK3BCDK7
SCHEMBL1748782 0.84 IGF1R (0.53) IGF1RLCKGSK3AGSK3BCDK7
SCHEMBL1748818 0.84 IGF1R (0.64) IGF1RLCKGSK3AGSK3BCDK7
SCHEMBL1749523 0.84 IGF1R (0.64) IGF1RLCKGSK3AGSK3BCDK7
SCHEMBL1748739 0.83 IGF1R (0.57) IGF1RLCKGSK3AGSK3BCDK7
SCHEMBL1749262 0.83 IGF1R (0.60) IGF1RLCKGSK3AGSK3BCDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968566-B2 Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2011-06-28 US disclosed
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2009-09-17 US disclosed
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US disclosed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US disclosed
CN-1950083-A Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA SA (FR) 2007-04-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885LCK 176/4885GSK3A 623/4885
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885LCK 176/4885GSK3A 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.